Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS: Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS: Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy –1.3% vs. –0.9% [–14 vs. –9 mmol/mol], estimated treatment difference [ETD] –0.4% [95% CI –0.6, –0.3] [–5 mmol/mol (–6, –3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (–1.4% vs. –0.9% [–15 vs. –9 mmol/mol], ETD –0.5% [95% CI –0.7, –0.4] [–6 mmol/mol (–7, –5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product −4.7 vs. −3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS: Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in the randomised, open-label, multinational 52-week PIONEER 2 trial, oral semaglutide 14 mg resulted in a significantly greater reduction in CRP compared with empagliflozin 25 mg.23”
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [20]
In the citing paper
“In PIONEER 2, oral semaglutide reduced CRP by 30%, whereas empagliflozin had no effect despite similar approximately 4% weight loss (24).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [24]
In the citing paper
“In the PIONEER program, four thyroid malignancies occurred in semaglutide-treated patients, versus one in the comparator group”
From Safety of Semaglutide (2021) · cites this paper as [15]
In the citing paper
“The ‘PIONEER’ series of trials [21–30] demonstrated that oral semaglutide has a positive impact on average HbA1c levels and weight reduction compared with several other drug classes (SGLT-2 inhibitor, DPP-4 inhibitor, another GLP-1RA, insulin and placebo).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [22]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†An episode that is severe, according to theADAclassification (requires assistanceof anotherperson to actively administer carbohydrate, glucagon, or other corrective action) (29).”
BackgroundUser’s manual for the SF-12v2 health survey
Ware, J., Kosinski, M., Bowker, D., Gandek, B., Ware, J. E., & Turner‐Bowker, D. M. (2002) · Cited by 1,085
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Self-citationSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Cited by
Items 301–400 of 482
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
Ren, H., Berry, S., Malkin, S. J. P., Hunt, B., & Bain, S. C. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070473 · Cited by 4
Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study
Alsheikh, A., Alshehri, A., ALZAHRANI, S. H., Jammah, A. A., Alqahtani, F., Alotaibi, M. S., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M. S., et al. (2024) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2024.100209 · Cited by 4
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
Abdelrahman, A. M., Awad, A. S., Hasan, I., & Abdel‐Rahman, E. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247732 · Cited by 4
Wang, T., Cui, Y., & Liao, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01689-1 · Cited by 5
Palazzi, S., Sentinelli, F., Zugaro, A., Morgante, S. N., Santarelli, L., Melanzi, S., Mutiis, A. D., Piersanti, D., Macerola, B., Iezzi, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060856 · Cited by 5
Agonistas de GLP-1 en el control glucémico y ponderal de la diabetes tipo 2. Nuevas perspectivas
Alonso, S. P., Valdés, S., & Doulatram‐Gamgaram, V. K. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107042 · Cited by 4
Sato, G. E., Uchino, H., & Hirose, T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01631-5 · Cited by 4
GLP‐1: A Prospective Guardian for Comprehensive Myocardial Perfusion
Li, Z., Yu, Y., Li, J., Jiang, X., Chen, J., Ye, N., Wu, B., Sun, Y., & Sun, G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70004 · Cited by 5
Oral GLP-1 Receptor Agonists for Weight Loss
Krinsky, D., Marcucci, A., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000833 · Cited by 4
Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India
Dutta, A., Mahendru, S., Sharma, R., & Mithal, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_266_24 · Cited by 4
ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum
Luca, L. D., Bilato, C., Navazio, A., Corda, M., Milli, M., Scicchitano, P., Marco, M. D., Riccio, C., Geraci, G., Iacovoni, A., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf071 · Cited by 4
Wehler, E., Lautsch, D., KOWAL, S. L., Davies, G., Briggs, A. H., Li, Q., Rajpathak, S. N., & Alsumali, A. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00967-7 · Cited by 5
Cui, J., Klepser, D. G., & McAdam‐Marx, C. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.840 · Cited by 4
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report
Alromaih, A., Alshamrani, A., Alharbi, B., Alharbi, I., Alharbi, T., Bokhari, S., Elbadawi, H., Almehthel, M. S., Alsaeed, A. H., Alyahia, K., et al. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.132017 · Cited by 4
Bhattacharyya, S., Saboo, B., Mohit, M., Bhojane, S., Deshmane, R., Chavda, V., Hasnani, D., Jagadeesha, A., & Sikdar, M. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_15_23 · Cited by 4
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
Chadwick, J., Berry, C., Carpenter, M. A., Gulati, G., Heck, S. L., Hinterberg, M., Holman, R. R., Lee, M. M. Y., Omland, T., Paterson, C., et al. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70077 · Cited by 3
Sanyal, D., Saboo, B., Phatak, S., Kumar, P. K. M., Basu, D., Verma, N., NAIR, A., Bhattacharjee, K., Aneja, P., Makkar, B. M., et al. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_179_25 · Cited by 3
Voetmann, L. M., Rolin, B., Kirk, R. K., Knudsen, L. B., Merkestein, M., Ahnfelt‐Rønne, J., Kodal, A. L. B., Jessen, C., Ozen, A. I., Pyke, C., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70510 · Cited by 3
Fériz, K., Rincón, A. R., Tovar, H., Restrepo-Erazo, K., Yepes, C. A., Brito, E. M., Gómez, N. B., Amézquita, Y. C. H., Iriarte-Durán, M. B., Jimenez, L., et al. (2025) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.12.3.907 · Cited by 3
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Carlander, A. F., Kaltoft, M., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01247-x · Cited by 4
Self-citationFirst-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
Pantanetti, P., Ronconi, V., Mancin, S., Carolis, C. D., Alberti, S., Pazzi, O., Marco, S. D., Michetti, G., Coacci, S., Mignini, V. E., et al. (2025) · Diabetology · doi:10.3390/diabetology6080080 · Cited by 3
Ding, L., Sun, B., Xiao, X., & Kin, T. (2020) · International Journal of Endocrinology · doi:10.1155/2020/1626484 · Cited by 3
Шамхалова, М. Ш., & Shestakova, M. V. (2022) · Diabetes Mellitus · doi:10.14341/dm12941 · Cited by 3
Wehrman, G., Halton, M., Riveland, B., Potter, E. M., & Gaddy, M. A. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221134174 · Cited by 5
Ray, S., Kapoor, N., Deshpande, N., Chatterjee, S., Kumar, J. S., Tantia, O., Goyal, G., Mukherjee, J. J., & Singh, A. K. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2330468 · Cited by 3
Sood, A., Sawhney, A., Borokhovsky, B., Vyas, A. V., & Gupta, R. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2462671 · Cited by 3
Ostrominski, J. W., Aroda, V. R., Braae, U. C., Kruse, C., Mandavya, K., & Buse, J. B. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01751-6 · Cited by 2
Chen, L., Huang, L., Zhang, H., Chen, Q., Zhang, Z., Huang, S., Li, F., Guan, J., & Yang, Y. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106982 · Cited by 3
Fadini, G. P., Longato, E., Poletto, S., Giaccari, A., Ghiani, M., Strazzabosco, M., Trombetta, M., Penno, G., Avogaro, A., Solini, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70151 · Cited by 3
Postema, A., Gaspersz, J., Baak, B. N., Huisman, E. L., Hoogstraten, C., Hagelund, L. M., Beest, F. J. A. P., & Overbeek, J. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70251 · Cited by 2
Piccione, A., Bonsangue, M., Barone, M., Vigneri, E., Mineo, M. I., Tomasello, L., Maniscalco, L., Pantò, F., Arnaldi, G., & Guarnotta, V. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104462 · Cited by 2
ElBadawi, H., Albalkhi, N., Kadhim, I. A., Elsadig, A. E., Baltzis, D., Hatahet, M. H., Ismail, M., Khader, S., Rasmussen, C. L., Scheuer, S. H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70317 · Cited by 2
Checa-Ros, A., Okojie, O. J., Steib, N., Bellasi, A., Salvador-Martínez, P., Isabel, F., & D’Marco, L. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04965-6 · Cited by 2
Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2
Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation
Deng, B., Kireev, V. A., Melentyeva, K. V., Kovalenko, I., & Pakhomov, O. V. (2020) · Problems of Cryobiology and Cryomedicine · doi:10.15407/cryo30.01.034 · Cited by 2
Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2
Escobar, C., Castro, A., Cerezo, J. F. G., Górriz, J. L., Obaya, J. C., & Villar‐Taibo, R. (2022) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(22)00013-9 · Cited by 7
Mohanan, P. P., & Jariwala, P. V. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.11.010 · Cited by 2
Bai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 2
Rosenstock, J., Cariou, B., Eliasson, J., Frappin, G., Kaltoft, M. S., Montanya, E., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15339 · Cited by 2
Self-citationTakubo, M., Watanabe, K., Saito, H., Kohno, G., & Ishihara, H. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2307-8036 · Cited by 2
Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis
Bandyopadhyay, I., Dave, S., Rai, A., Nampoothiri, M., Chamallamudi, M. R., & Kumar, N. (2021) · Current Drug Targets · doi:10.2174/1389450122666210901125420 · Cited by 2
Li, W. (2024) · Qeios · doi:10.32388/fgtlkf · Cited by 2
Gilyarevskiy, S. R. (2021) · Kardiologiia · doi:10.18087/cardio.2021.4.n1549 · Cited by 2
Oral Semaglutide: A Novel Oral Preparation of GLP-1 Receptor Agonist
Mohan, B. P., & Eligar, V. S. (2021) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410146 · Cited by 1
Fisher, M., Llano, A., & McKay, G. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch5 · Cited by 1
Clinical translation of oral peptide delivery technologies
Tyagi, P., & Subramony, J. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821061-1.00020-4 · Cited by 2
Kesavadev, J., Unnikrishnan, A. G., Sanyal, D., Aneja, P., & Saboo, B. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_17_22 · Cited by 1
Raskar, V., Singh, S. K., Suri, S., Shankar, P., Sonawane, A. B., Hasnani, D., & Chavda, V. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_7_23 · Cited by 1
Alluhidan, M., Alabdulkarim, H. A., Alrumaih, A. M., Alturaiki, A., Alshahrani, A. M., AL-Qahtani, S. S., Alhossan, A., & Al-Jedai, A. H. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2277056 · Cited by 2
Real-world Use of Oral Semaglutide in Patients with Type 2 Diabetes in India: A Retrospective Study
Chittawar, S., Suri, S., Garg, A., Gupta, V., Patni, B., Mitra, A., Handral, A., Desai, A., Aggarwal, R., & Goyal, R. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_31_24 · Cited by 1
Lora-Escobar, S. J., Francisco, L. R.-D., López-Feijoo, M., Santos‐Ramos, B., Bellido, V., Mejía, R. M. C., & Acosta-García, H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/3733178 · Cited by 1
Role of Dapagliflozin versus Empagliflozin as add-on Therapy on Diabetic Nephropathy
Najim, H. D., Mohammed, M. M., & Rahmah, A. M. (2025) · Palestinian medical and pharmaceutical journal/Palestinian medical & pharmaceutical journal · doi:10.59049/2790-0231.10.4.2410 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Tada, H., & Takamura, M. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6198-25 · Cited by 1
Renna, N. F., Ramirez, E. I., Arrupe, M. F., & Ramirez, J. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004158 · Cited by 1
Seighali, N., Chahkand, M. S. G., Ebrahimzade, M., Arashlow, F. T., Maroufi, S. P., Rahnama, P., Matin, M. H., Javazm, A. K., Ebrahimi, P., Nasir, K., et al. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01149-5 · Cited by 2
Malighetti, M. E., Vescini, F., Carpentieri, M. S., Altomari, A., Turchi, F., Porto, A. D., & Dauriz, M. (2025) · Minerva Endocrinology · doi:10.23736/s2724-6507.25.04376-3 · Cited by 1
Garma, J. L., Mouce, C. G., Novo, N. R., Trastoy, O. D., Nieto, A. S., Castro, P. P., Díaz-Ortega, C., Fernández-Rodríguez, E., Carballeira, R. P., Pinal-Osorio, I., et al. (2026) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2026.501713 · Cited by 3
Ma, Y., Lin, Y., Ding, X., & Peng, Y. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70176 · Cited by 1
Kim, E. Y., & Feinstein, M. J. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.02.024 · Cited by 5
Giaccari, A., Borroni, F., Dauriz, M., Gioia, D., Baptiste, P. J., Bisio, A., Lastoria, G., Udupa, K., & Barbagallo, M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113244 · Cited by 1
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Zhou, L., Wu, P., Xu, Y., & Xie, B. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02697-2 · Cited by 2
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Jena, S., Jindal, R., Dutta, D., Kamrul-Hasan, A. B. M., & Mahajan, K. (2026) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2026.22.1.8 · Cited by 2
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Jagtap, N., Golchha, A., Katrevula, A., Asif, S., Rughwani, H., Koduri, K. K., Balenki, P., Kalapala, R., & Reddy, D. N. (2026) · Endoscopy · doi:10.1055/a-2891-4165 · Cited by 1
Vadén, A., Lahelma, M., NURMI, L., Heikkilä, E., Vessari, H., Luoto, H., Saukkonen, T. T., & Niskanen, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70920 · Cited by 1
Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders
Russjan, E., Zając, D., & Kaczyńska, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135803 · Cited by 1
Oral Adverse Effects of Semaglutide Therapy: A Narrative Review
Al-Zawawi, A. S. (2026) · Journal of International Society of Preventive and Community Dentistry · doi:10.4103/jispcd.jispcd_5_26 · Cited by 1
Ortiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Larger, É. (2021) · médecine/sciences · doi:10.1051/medsci/2020261 · Cited by 2
Targeting Islet GPCRs to Improve Insulin Secretion
Atanes, P., Ruz‐Maldonado, I., & Persaud, S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00050-5 · Cited by 1
and, C. R., & Petrie, J. R. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch6 · Cited by 1
Mannucci, E., & Ghetti, G. (2022) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v23i1.1539 · Cited by 1
A kardiometabolikus rizikó csökkentésének fontossága 2-es típusú cukorbetegségben
Kempler, P. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.s1.3 · Cited by 1
Pharmacologic management for polycystic ovary syndrome: Weight loss
Nadeem, S., & Merchant, A. A. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87932-3.00025-6 · Cited by 1
GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks
Dębik, M., Szydłowski, Ł., Żurowska, K., Bednarski, A., Krużel, A., Ziajor, S., Sajdak, P., Tomasik, J. M., Stodolak, M., & Kłos, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.62.014 · Cited by 1
Oral Anti-Diabetic Semaglutide: A GLP-1 RA Peptide
Kahol, R., Jain, A., Sharma, N., & Mishra, S. K. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24jun1950 · Cited by 1
Re-imagining Oral Semaglutide in Routine Clinical Practice: Indian Expert Panel Recommendations
Jagadeesha, A., Saboo, B., WANGNOO, S. K., Gangopadhyay, K. K., Kesavadev, J., Bantwal, G., Kalra, P., Thacker, H. P., & PATANGE, S. A. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_18_25 · Cited by 1
Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling
Kalra, S., Kalhan, A., & Berard, L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1809906 · Cited by 1
A one-dimensional semaglutide-GLP-1R-based mini static GIBACPreprint
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202406.0953.v1 · Cited by 1
Los arGLP1: una oportunidad para el tratamiento del riesgo cardiometabólico
Miramontes‐González, J. P. (2021) · doi:10.52102/contexto_epidemiologico/art-3
Studying the interactions of IT/IS and human resource management in multicultural societies.
Siakas, K. V., & Georgiadou, E. (2003)
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review2
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/decision1
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/decision1
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review3
Reifsnider, O. S., Pimple, P. M., Brand, S. B., Washington, E. B., Shetty, S. S., & Desai, N. R. (2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/response1
A semaglutida oral irá substituir a cirurgia metabólica? Revisão sistemática
Guimarães, A. P. S. E. S., Sendin, A. L., & Campolina, C. D. O. C. (2022) · STUDIES IN HEALTH SCIENCES · doi:10.54022/shsv3n2-009 · Cited by 1
Semaglutide: A Strategic Weapon for Primary Care
Jain, A. (2022) · The Singapore Family Physician · doi:10.33591/sfp.48.3.u3
A korai erélyes glikémiás kontroll jelentősége 2-es típusú cukorbetegségben
Hosszúfalusi, N. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.s1.2
Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
Kuriyama, S., & Matsumoto, K. (2022) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.53.6_249
Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control
La Salle, J., Uusinarkaus, K., Family Medicine, C. P. C., Marso, S. P., Cardiovascular Medicine, H. M. H., & Pantalone, K. M. (2023) · Journal of Family Medicine · doi:10.26420/jfammed.2023.1325
Sodium-Glucose Cotransporter 2 Inhibitors
DAILEY, G. E., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_36
Characteristics of the Latest Therapeutic Agent for Diabetes
Yun, N. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.148
Metadata
- Authors
- Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., PIONEER 2 Investigators, Cruz, P., Loredo, L. D., Luquez, C., Moisello, M., Augusto, G. A., Castro, M., Canani, L., Akrap, B., Bulum, T., Rahelic, D., Sunic-Grcic, I., Tusek, S., Avramidis, I., Benroubi, M., Didangelos, T., Karousos, G., Pagkalos, E., Sampanis, C., Somali, M., Domboróczki, Z., Faludi, P., Gaál, Z., Kis-Gombos, P., Kocsis, G., Marton, Z., Sudár, Z., Buscemi, S., Di Carlo, A., Dotta, F., Gambineri, A., Lauro, D., Maranghi, M., Arciszewska, M., Gumprecht, J., Matuszewska, K., Skokowska, E., Stasinska, T., Feofanova, S., Filippova, E., Galstyan, G., Gaysina, L., Kunitsyna, M., Suplotova, L., Antic, S., Djukic, A., Mitrovic, M., Pesic, M., Stokic, E., Jodar, E., Martínez, E., Raya, P. M., Montanya, E., Portillo, C. M., Vera, M. P., Fernández, M. R., San Jose, P., Riera, M. T., Boonyavarakul, A., Deerochanawong, C., Sriwijitkamol, A., Ajani, D., Armas, E., Barbel-Johnson, K., Bartilucci, D., Bonabi, G., Busch, R., Butuk, D., Cannon, K., Chase, C., Chaykin, L., Cheekati, V., Davis, T., Delgado, B., Farris, N., Graves, M., Ha, C., Harper, L., Herring, S., Hewitt, M., Hsia, D., Jackson, R., Jardula, M., Joyce, M., Juarez, M., Kapoor, A., Karounos, D., Kayne, D., Lacour, A., Ledesma, G., Lingvay, I., Lipetz, R., Lomboy, J., Lynd, S., Morawski, E., Morin, R., Murphy, R., Overcash, J. S., Pullman, J., Rodbard, H. W., Rosenstock, J., Ruoff, G., Steenkamp, D., Toro, H., Trachtenbarg, D., Tulloch, B., Weisbrot, A., & Wright, A.
- Affiliations
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Novo Nordisk (Denmark) (DK)
- ORCID
- Lindberg, Søren Østergaard
- Augusto, Gustavo Akerman
- Bulum, Tomislav
- Avramidis, Iakovos
- Didangelos, Triantafyllos
- Buscemi, Silvio
- Dotta, Francesco
- Gambineri, Alessandra
- Lauro, Davide
- Maranghi, Marianna
- Galstyan, Gagik
- Boonyavarakul, Apussanee
- Sriwijitkamol, Apiradee
- Busch, Robert
- Herring, Sharon
- Hsia, Daniel
- Overcash, J. Scott
- Steenkamp, Devin
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-10-07
- Volume
- 42
- Issue
- 12
- Pages
- 2272-2281
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2974621372
- Cited by
- 463
- References
- 37
- Citations by year
- 2026: 53 · 2025: 85 · 2024: 78 · 2023: 55 · 2022: 64 · 2021: 59 · 2020: 60 · 2019: 8
- FWCI
- 38.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Use Siena air (University of Siena) (submittedVersion)
- Lume (Universidade Federal do Rio Grande do Sul) (submittedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- oral semaglutide, empagliflozin, type 2 diabetes, metformin failure, GLP-1 receptor agonists, SGLT2 inhibitors, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, drug safety, treatment policy estimand
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.